Amneal Reports the Commercial Availability of Fylnetra (biosimilar, pegfilgrastim) in the US
Shots:
- The company launch Fylnetra, a biosimilar referencing Neulasta in the US making it the sixth biosimilar for febrile neutropenia. The biosimilar was developed in collaboration with Kashiv Biosciences
- The company focuses to provide high-quality biosimilars to the global markets over the coming years. The biosimilar product is intended to lower the incidence of inf. as manifested by FN in patients with non-myeloid malignancies on myelosuppressive anticancer drugs
- Fylnetra is supplied as a 6mg/0.6mL preservative-free solution in single-dose prefilled syringes for SC inj. The US FDA approved Fylnetra, a leukocyte growth factor based on data demonstrating a high degree of similarity over reference products with no clinical differences
Ref: Amneal | Image: Amneal
Related News:- Amneal & Kashiv Receive the US FDA’s Approval for Fylnetra (biosimilar, pegfilgrastim)
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
